They told me it was effective, and I knew mailing a Cologuard box back would be pretty dang easy.” Cologuard — a simple way ...
The Cologuard Plus test demonstrated 95% sensitivity for colorectal cancer detection at 94% specificity, making it the most accurate noninvasive CRC screening test reported in studies to date Building ...
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will present modeling data evaluating the ...
Forbes contributors publish independent expert analyses and insights. Physician who writes about the rising rates of cancer in young adults. This voice experience is generated by AI. Learn more. This ...
On Friday, the FDA approved Exact Sciences Corp.’s (NASDAQ:EXAS) Cologuard Plus test, the company’s next-generation multi-target stool DNA test. The Cologuard Plus test is now approved for adults ages ...
Jeff Smith was dumbfounded when he received a colon cancer screening kit in the mail. The 68-year-old Minnesota man hadn't asked for the Cologuard test, and his doctor hadn't mentioned anything about ...
Please provide your email address to receive an email when new articles are posted on . Compared with the original Cologuard test approved by the FDA in 2014, the company’s next-generation test uses ...
The nationwide rollout, which Labcorp disclosed Monday, comes weeks after the Centers for Medicare and Medicaid Services approved coverage for ColoSense, and the American Cancer Society named the test ...
Bernstein lifted its Guardant Health price target to $200 after UnitedHealth's Shield coverage decision. Here's what it means ...
(RTTNews) - Exact Sciences Corp. (EXAS) Monday has introduced Cologuard Plus, an FDA-approved noninvasive colorectal cancer - CRC screening test for average-risk adults aged 45 and older. It offers 95 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results